NASDAQ:LPTX Leap Therapeutics (LPTX) Stock Price, News & Analysis $0.39 0.00 (-0.48%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Leap Therapeutics Stock (NASDAQ:LPTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Leap Therapeutics alerts:Sign Up Key Stats Today's Range$0.38▼$0.4050-Day Range$0.27▼$0.5052-Week Range$0.22▼$4.79Volume482,157 shsAverage Volume820,305 shsMarket Capitalization$16.22 millionP/E RatioN/ADividend YieldN/APrice Target$4.92Consensus RatingHold Company OverviewLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Read More… Leap Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreLPTX MarketRank™: Leap Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 592nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingLeap Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageLeap Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Leap Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Leap Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Leap Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.45% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Leap Therapeutics has recently increased by 147.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.45% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Leap Therapeutics has recently increased by 147.40%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for LPTX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows5 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Leap Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.46% of the stock of Leap Therapeutics is held by institutions.Read more about Leap Therapeutics' insider trading history. Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LPTX Stock News HeadlinesLeap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerApril 15, 2025 | prnewswire.comLeap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study TranscriptMarch 31, 2025 | seekingalpha.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 25, 2025 | Golden Portfolio (Ad)H.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)March 27, 2025 | markets.businessinsider.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | finanznachrichten.deLeap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | prnewswire.comLeap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | prnewswire.comSee More Headlines LPTX Stock Analysis - Frequently Asked Questions How have LPTX shares performed this year? Leap Therapeutics' stock was trading at $2.88 at the beginning of 2025. Since then, LPTX stock has decreased by 86.4% and is now trading at $0.3931. View the best growth stocks for 2025 here. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics, Inc. (NASDAQ:LPTX) announced its quarterly earnings results on Wednesday, March, 26th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. When did Leap Therapeutics' stock split? Leap Therapeutics's stock reverse split on the morning of Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Leap Therapeutics? Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Vaxart (VXRT) and OPKO Health (OPK). Company Calendar Last Earnings3/26/2025Today4/24/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LPTX CIK1509745 Webwww.leaptx.com Phone(617) 714-0360FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$4.92 High Stock Price Target$8.00 Low Stock Price Target$1.25 Potential Upside/Downside+1,150.7%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.24% Return on Assets-93.18% Debt Debt-to-Equity RatioN/A Current Ratio3.97 Quick Ratio3.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book0.17Miscellaneous Outstanding Shares41,258,000Free Float36,249,000Market Cap$16.22 million OptionableOptionable Beta0.22 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:LPTX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.